SUTRO BIOPHARMA, INC. Total Liabilities and Equity
SUTRO BIOPHARMA, INC. (STRO) had Total Liabilities and Equity of $194.46 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-12
- 2026-06-30: Liabilities and Equity $194.46M.
- 2026-03-31: Liabilities and Equity $241.99M.
- 2025-12-31: Liabilities and Equity $173.83M.
- 2025-09-30: Liabilities and Equity $209.66M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $194.46M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $241.99M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $173.83M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $209.66M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $262.36M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $321.43M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $387.21M 10-K · filed 2026-03-23 |
| 2024-09-30 | $451.83M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $489.04M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $403.40M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $470.74M 10-K · filed 2025-03-13 |
| 2023-09-30 | $431.73M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $464.90M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $358.02M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $406.94M 10-K · filed 2024-03-25 |
| 2022-09-30 | $400.70M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $385.62M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $303.68M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $341.41M 10-K · filed 2023-03-30 |
| 2021-09-30 | $371.47M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $359.79M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $358.53M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $394.11M 10-K · filed 2022-02-28 |
| 2020-09-30 | $307.24M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $277.54M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $153.88M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $156.37M 10-K · filed 2021-03-18 |
| 2019-09-30 | $171.68M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $188.81M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $202.46M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $223.14M 10-K · filed 2020-03-16 |
| 2018-09-30 | $145.03M 10-Q · filed 2018-11-14 |
| 2017-12-31 | $40.77M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |